The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally. The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
The Cancer Research UK Cancer Therapeutics Unit (CTU), within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The Cancer Therapeutics Unit’s exciting goal is to discover high quality small molecule drug candidates and to progress these to clinical trial. All the scientific disciplines are in place to make this possible, including medicinal chemistry, biology, drug metabolism and clinical specialists who focus on new molecular targets emerging from human genome and ground breaking cell biology research.
Two Higher Scientific Officer position are now available in the Hit Discovery and Structural Design Team within the Unit. The team combines small-molecule high throughput screening, assay development and High-Throughput Screening with fragment-based hit discovery, biophysical assays and X-ray crystallography to enable structure-based drug design within the Unit. These methodologies are underpinned by state-of-the art protein _expression_, purification and characterisation capabilities, allowing for the generation of large quantities of high quality protein targets. Successful candidates will be integral members of a multidisciplinary project teams and will interact closely with the biologists, computational chemists, medicinal chemists and structural biologists.
One of the positions (ref 304) focusses on recombinant protein production for one of the cancer targets under study at the Unit. The successful candidate will be involved in performing the _expression_, purification and characterisation of one of our early stage drug targets, using contemporary _expression_ systems and purification methods available within the Team. In addition, the post-holder is expected to characterise ligand and inhibitor binding to the recombinant proteins using biochemical and biophysical methods. Applicants must have a BSc in a biochemistry or related biological subject and in depth technical laboratory experience in protein _expression_ and purification methodologies preferably related to drug discovery. Expertise in insect cell _expression_, assay development and/or knowledge of structural biology would be advantageous. The starting salary for the position will be in the range of £32,628 - £36,622 p.a. inclusive (based on previous experience) and the post is offered on a fixed term contract of 2 year. Informal enquiries to email@example.com
The second position (ref 303) is in collaboration with the Cancer Biomarkers Team led by Prof. Johann de Bono. The successful candidate will use molecular and cell biology to develop cell-based assays for the screening of compound libraries and the profiling of cellular activities of inhibitors for a key cancer target. The post-holder is expected to apply detailed technical knowledge to develop, execute and analyse novel cell-based luciferase reporter assays for this target. Applicants must have a degree in Biochemistry, Molecular Biology or Cell biology and good technical laboratory experience in mammalian cell culture, molecular and cell biology methodologies is essential. Knowledge of reporter assays and drug discovery would be desirable. Appointment will be to a Higher Scientific Officer with starting salary in the range of £32,628 to £33,961 p.a. inclusive and the post is offered on a fixed term contract of 1 year in the first instance and benefits from a contributory defined benefit pension scheme and generous leave entitlement Informal enquiries to firstname.lastname@example.org or email@example.com
The closing date for both positions is January 4th 2018.
Please DO NOT send your application to Dr van Montfort or Dr Burke, but see our website for more details and on how to apply: www.icr.ac.uk.
The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP.
This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network.